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in expression of GSDMB transcripts
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Tim Frayling2 and Lorna W Harries1*Abstract
Background: Many genetic variants have been associated with susceptibility to complex traits by genome wide
association studies (GWAS), but for most, causal genes and mechanisms of action have yet to be elucidated. Using
bioinformatics, we identified index and proxy variants associated with autoimmune disease susceptibility, with the
potential to affect splicing of candidate genes. PCR and sequence analysis of whole blood RNA samples from
population controls was then carried out for the 8 most promising variants to determine the effect of genetic
variation on splicing of target genes.
Results: We identified 31 splice site SNPs with the potential to affect splicing, and prioritised 8 to determine the
effect of genotype on candidate gene splicing. We identified that variants rs11078928 and rs2014886 were
associated with altered splicing of the GSDMB and TSFM genes respectively. rs11078928, present in the asthma and
autoimmune disease susceptibility locus on chromosome 17q12-21, was associated with the production of a novel
Δ exon5-8 transcript of the GSDMB gene, and a separate decrease in the percentage of transcripts with inclusion of
exon 6, whereas the multiple sclerosis susceptibility variant rs2014886, was associated with an alternative TFSM
transcript encompassing a short cryptic exon within intron 2.
Conclusions: Our findings demonstrate the utility of a bioinformatic approach in identification and prioritisation of
genetic variants effecting splicing of their host genes, and suggest that rs11078928 and rs2014886 may affect the
splicing of the GSDMB and TSFM genes respectively.
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Genome wide association studies (GWAS) have greatly
increased our understanding of the genetic basis of
many complex diseases and traits by identifying single
nucleotide polymorphisms (SNPs) that act as susceptibil-
ity factors for these diseases [1,2]. However, the results
of GWAS only give us a genomic region associated with
a particular disease or trait, and the causal SNP, gene
and importantly, mechanism of action remain elusive.
To date, only a handful of SNPs have been demonstrated* Correspondence: L.W.Harries@exeter.ac.uk
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reproduction in any medium, provided the oras causal for a particular disease and the mechanism
whereby the SNP confers disease risk identified. For ex-
ample, GWAS has identified hundreds of loci associated
with susceptibility to inflammatory or autoimmune dis-
eases such as Crohn’s disease, asthma, multiple sclerosis
(MS) and type 1 diabetes (T1D), furthering our under-
standing of the genetic basis of these diseases and identi-
fying areas of the genome for further study [3]. However,
apart from a variant in the immunity-related GTPase
family, M (IRGM) gene, which has been shown to confer
susceptibility to Crohn’s disease by altering miRNA
binding at the site of the SNP [4], the causal genes and
mechanisms in most cases remain to be identified.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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by GWAS into a fuller understanding of which genes are
associated with disease, and their mechanistic actions,
could be a reflection of the focus on protein coding vari-
ants, whereas most SNPs are in fact within non-coding
regions of the gene [5,6]. At least 80% of the human
genome has now been demonstrated to contain import-
ant regulatory sequences such as enhancers, silencers,
small RNA binding sites and chromatin modifiers [7-12].
An important mechanism of gene regulation, alternative
splicing, is a complex process requiring over 100 splicing
factors that recognise regulatory elements such as
exonic and intronic splicing enhancers and silencers
(ESEs, ESSs, ISEs, ISSs), which bind trans-acting splicing
regulatory factors [13] that bind to the mRNA
secondary structure [14]. Regulatory elements include
the splice acceptor AG, the polypyrimidine tract, the
splice donor GT and the branch site adenosine residue
[13]. In addition disruption of any of these sequences
has the potential to alter splicing by re-directing
the spliceosome or by altering binding of auxiliary
factors to exonic and intronic splicing enhancers and
silencers.
In this study, our aim was to follow a bioinformatic
pipeline in order to identify autoimmune disease-
associated variants with the potential to effect splicing,
and to follow up interesting candidate variants by
mRNA analysis in whole blood, an appropriate tissue for
the analysis of autoimmune or inflammatory disorders.
In this article, we report two variants in two genes that
exhibit a genotype-associated effect on mRNA process-
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Figure 1 Bioinformatic pipeline used to predict splice site SNPs that a
Index inflammatory SNPs were identified that had been associated by GWA
The proxies to these GWAS SNPs were pulled using the SNAP Proxy Search
each SNP was identified as being ‘Splice Site’ or ‘Essential Splice Site’ using
bioinformatically analysed to predict whether a splicing change was likely t
predicts ESE element sequences that are bound by SR proteins), NNSplice
in a given sequence) and Alamut (splicing mutation prediction programme
algorithms to identify potential core splice sites in a given gene transcript)
splicing by RT-PCR. The numbers in brackets denote how many SNPs wereResults
SNPs associated with autoimmune or inflammatory
diseases are enriched for splice site variants
We performed a series of bioinformatic analyses to iden-
tify genetic variants that could potentially alter splicing of
their host genes (Figure 1). 338 SNPs associated with one
or more autoimmune diseases or inflammatory traits were
identified that reached genome wide significance, and
7322 proxies were identified to these index SNPs. Of
these, 31 SNPs were annotated as ‘splice_region_variant’
using the Biomart program (Ensembl; http://www.
ensembl.org). When compared to 1000 sets of 338
random SNPs and their proxies, we found that 0.41% vari-
ants associated with autoimmune or inflammatory pheno-
types were located in splice regions, compared with a
mean of 0.28% for randomly selected variants (one tailed
t-test p = 0.028; Figure 2), indicating that inflammatory or
autoimmune SNPS were enriched for splice site variants.
Two SNPs in splice site regions were shown to produce
alternative splice products
8 variants were prioritised for further analysis on the
basis that they had the potential to create cryptic splice
sites, interrupt polypyrimidine tract sequences or disrupt
regulatory elements involved in splicing. The 8 variants
prioritised for further analysis using this pipeline are
shown in Table 1. Unusual bands were identified for half
of the variants tested upon RT-PCR (rs11078928
(GSDMB), rs2014886 (TSFM), rs1260326 (GCKR) and
rs3764021 (CLEC2D). Two bands (GCKR, CLEC2D)
were artifactual, and the remaining two (GSDMB, TSFM)
were further characterized and sequenced. We found noIdentification of functional 
consequence for each SNP 
using ENSEMBL BioMart
 of proxy 
index SNPS 
(n = 7322)
Variants potentially 
affecting Splice sites 
identified. (n = 31)
nalysed 
ly using ESE 
and Alamut
ing changes.
re associated with autoimmune diseases and inflammatory traits.
S with susceptibility to autoimmune diseases and inflammatory traits.
tool (Broad Institute). The ‘functional consequence to transcript’ for
the Biomart function of Ensembl. These SNPs were then
o occur, using the programmes ESE finder (web-based tool that
(web-based tool that algorithmically predicts core spice site sequences
that amalgamates predictions from five different splice site prediction
. A subset of SNPs was then prioritised for further analysis of their
identified at each stage.
Figure 2 Enrichment of variants associated with inflammatory or autoimmune phenotypes in splicing control regions. We assessed the
number of randomly selected variants located in splicing control elements by chance. For each set of 338 ‘index’ SNPs and their proxies, the
percentage of variants located in ‘splice region elements’ is given on the X-axis (simulated percentage), and the number of SNPs at each
percentage (count) is given on the Y-axis. The observed number of autoimmune or inflammatory SNPs located in ‘splice region elements’ is given
by the line.
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http://www.biomedcentral.com/1471-2164/14/627evidence of altered splicing caused by the remaining vari-
ants, although we cannot rule out splicing changes not
identified because of primer placement or transcript levels.
Rs11078928 causes two separate splicing changes in the
Gasdermin B (GSDMB) gene
We found two separate splicing changes associated with
the variant rs11078928 in the gene GSDMB. These
changes include production of a novel transcript of
GSDMB and a change in isoform ratio. The novel band
associated with rs11078928 was found upon sequence
characterisation to be a large deletion product lacking
exons 5–8 of the gene GSDMB (Figure 3A and
Additional file 1). To determine whether this deletion
was associated with genotype and therefore caused by
the variant rs11078928, we designed Taqman assays to
the wild-type and novel transcripts as described above
from the custom assay service available from Life Tech-
nologies (Life Technologies, Foster City, USA). We
found evidence to suggest a genotype-associated effect
on the expression levels of this deletion product; with
homozygotes for the major (A) allele, showing in-
creased expression of this alternate Δ5-8 transcript, and
homozygotes for the minor (G) allele showing negli-
gible expression of the transcript compared with het-
erozygous individuals or those homozygous for the A
allele (p = 0.0001; Figure 3B).Moreover, four reference transcript sequences are
described for this gene in expressed sequence tag
(EST) databases; two transcripts (NM_001165958.1
and NM_001165959.1) include exon 6, whilst this exon
is deleted in the remaining two (NM_001042471.1 and
NM_018530.2). Therefore, we quantified relative ex-
pression of these different isoforms according to geno-
type using Taqman Assays (Life Technologies, Foster
City, USA) (Additional file 2). Although there was no
significant change in expression of the isoforms lacking
exon 6, we found that the isoforms which include exon
6 have almost no expression in homozygotes for the
minor allele of rs11078928 compared with heterozy-
gous individuals, and those homozygous for the A
allele (p = 0.0002; Figure 3C). This striking genotype-
specific expression difference suggests that rs11078928
or an associated variant may be altering exon 6 inclusion
in the GSDMB transcript. The Alamut Mutation Interpret-
ation Software (Interactive Biosoftware, Rouen, France)
predicted that rs11078928 would result in deletion of
exon 6. We also quantified expression of the WT tran-
script and overall expression of GSDMB, to determine
whether these were altered by genotype. The expression
differences between genotypes showed decreased ex-
pression for those individuals carrying the minor allele,
although they did not reach statistical significance (re-
sults shown in Figure 3D-E).
Table 1 The 8 splice site SNPs prioritised for further analysis after following the bioinformatic pipeline set out
Proxy
(i.e. splice site SNP)
GWAS variants in
LD with splice site
SNPs
P value Phenotype
(risk allele)
PID r2 Host gene
of splice
site SNP
Alleles for splice
site SNP
Consequence
to transcript
Prediction/location
rs11078928 rs2872507 5 × 10-11 Ulcerative colitis (A) 21297633 1 GSDMB A > G Essential Splice
Site
Destroys AG of acceptor splice site intron
5: Predicted skip of exon 6 (Alamut)
rs2872507 5 × 10-9 Crohn’s disease (A) 18587394 1
rs9303277 2 × 10-9 Primary biliary cirrhosis
(T)
20639880 0.905
rs2290400 6 × 10-13 Type 1 diabetes (?) 19430480 0.905
rs7216389 9 × 10-11 (Asthma (T)) 17611496 0.905
rs2014886 rs703842 5 × 10-11 multiple sclerosis (A) 19525955 0.964 TSFM C > T Essential Splice
Site
Introduces cryptic donor splice site intron
2: Likely to result in alternative exon inclusion
rs1260326 rs780094 7 × 10-15 C-reactive protein (A) 18439548 0.933 GCKR T > C Splice Site 1 bp from GT of splice donor exon 15, alters
splice site score
rs780093 5 × 10-11 Crohn’s disease (T) 21102463 0.901
rs10263341 rs886774 3 × 10-8 Ulcerative colitis (G) 19915572 0.803 DLD T > C Splice Site May interrupt polpyrimidine tract intron 6
rs1322077 rs2301436 1 × 10-12 Crohn’s disease (T) 18587394 0.904 FGFR1OP T > C Splice Site May interrupt polpyrimidine tract intron 5
rs2020854 rs2066808 1 × 10-9 Psoriasis (A) 19169254 1 STAT2 A > G Splice Site May introduce cryptic donor site intron 14
rs55719896 rs8049439 2 × 10-9 Inflammatory bowel
disease, early onset (G)
19915574 0.965 ATXN2L G > A Splice Site Destroys AG of cryptic acceptor splice site
intron 20
rs4788084 3 × 10-13 Type 1 diabetes (G) 19430480 0.824
rs3764021 rs3764021 5 × 10-8 Type 1 diabetes (G) 17554300 1 CLEC2D C > T Splice Site May introduce cryptic donor splice site
exon 2
The table shows the 8 SNPs that lie within splice sites of the genes listed. The index GWAS autoimmune/ inflammatory SNPs that are in LD (r2 < 0.8) with the splice site SNPs are shown, as well as the splice site
prediction/location. PID PubMed Accession, LD linkage disequilibrium.
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Figure 3 Wild-type (WT) and Novel Variant (NV) isoforms of the GSDMB gene and their expression with genotype. A. Showing exons
4–9 of the four RefSeq isoforms and the novel GSDMB transcipt (GSDMB NV), which is missing exons 5–8. Half the Reference Sequence (WT)
transcripts include exon 6 and two are lacking exon 6; NM001165958.1 is the full length transcript. The star shows the position of rs11078928
(acceptor splice site of intron 5). The location of the Custom Taqman Assay Primers (indicated by an arrow) and probe (indicated by a rectangle)
are shown. B. Chart showing the expression of the novel transcript GSDMB NV by genotype. Homozygotes for the minor allele show negligible
expression of the novel transcript. Expression is normalised to the endogenous control RPLPO, and is shown relative to the expression of GSDMB
NV in heterozygotes. Significant results (P < 0.05) are indicated by an asterix. C. Chart showing the expression with genotype of the GSDMB
transcripts which include exon 6 (NM001165958.1, NM001165959.1). Homozygotes for the minor allele show no expression of exon 6-containing
transcripts. Expression is normalised to the endogenous control RPLPO, and is shown relative to the expression of exon 6 GSDMB transcripts in
heterozygotes. D-E. Charts showing total expression of GSDMB (all RefSeq isoforms, including novel) and expression of GSDMB WT (all RefSeq
isoforms). Expression is normalized to the endogenous control RPLPO, and is shown relative to total and WT expression respectively in
heterozygotes. Both show a decrease in expression with the minor allele, although these results did not reach statistical significance.
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http://www.biomedcentral.com/1471-2164/14/627Rs2014886 creates a cryptic donor splice site and alters
splicing of the Ts translation elongation factor, mito-
chondrial (TSFM) gene.
We identified a novel band in carriers of the ‘T’ allele
for rs2014886 which we were unable to isolate by con-
ventional means due to the large size of the product.
The size of the band (~530 bp) corresponded to a TSFM
transcript with the inclusion of a short exon, where thedonor site is created by rs2014886 and which has EST
(expressed sequence tag) evidence of use [15], but which
is not present in the reference sequence (RefSeq) tran-
scripts. This donor site is preceded by a strong acceptor
site that is present 38 bp upstream of the variant, which
also has evidence of use in EST databases [15] (Figure 4A
and Additional file 3). We therefore designed RT-PCR
primers specific to the predicted novel transcript, to
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Figure 4 WT and NV isoforms of TSFM and their expression with genotype. A. Showing exons 2–3 of the RefSeq transcript (there are four
RefSeq isoforms for TSFM, however, they are identical over this region of the gene) and the novel TSFM transcript (TSFM NV), which has an
alternate 38 bp exon included between introns 2 and 3. The star shows the relative position of rs2014886 (introducing an intronic donor splice
site within intron 2. B. Chart showing the expression of the novel transcript TSFM NV by genotype. Homozygotes for the major allele show
negligible expression of the novel transcript. Expression is normalised to the endogenous control RPLPO, and is shown relative to the expression
of TSFM NV in heterozygotes. Statistical significance is indicated by an asterix.
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http://www.biomedcentral.com/1471-2164/14/627confirm its identity. By this method, we were able to se-
quence the product and verify that the transcript in-
cludes a short 38 bp exon insertion within intron 2 of
TSFM (Figure 4A). Expression of the novel transcript
was found to be associated with genotype, with individ-
uals carrying two minor (T) alleles expressing the novel
transcript at levels approximately 2-fold higher than in-
dividuals carrying two major (C) alleles (p = 0.00005;
Figure 4B). However, we found no significant differences
in expression between individuals of different genotypes
for expression of total TSFM and TSFM WT.Discussion
Although hundreds of SNPs have been associated with
autoimmune diseases by GWAS [1,2] the causal gene
and mechanism in most cases remains elusive. We
prioritised 8 variants with bioinformatic evidence to alter
splicing by creating cryptic splice sites, interrupting
polypyrimidine tract sequences or disrupting regulatory
elements involved in splicing. Here we provide evidence
that a bioinformatic pipeline may be followed in order to
identify and prioritise variants that are likely to affect
splicing of their host gene. We have identified a
genotype-associated effect on alternative splicing for twoof the 8 SNPs (rs11078928 and rs2014886) on the pro-
cessing of the GSDMB and TSFM genes respectively.
Variant rs11078928 is associated with two separate
splicing changes in the gene GSDMB, which could pos-
sibly be of functional significance, whereas, the effect of
rs2014886, within TSHM most likely has little functional
consequence, since it is not affected by genotype. For
the remaining 6 SNPs, we found no evidence for altered
splicing. This could indicate that the SNPs in or near
these splice sites were too weak to re-direct the splicing
machinery, although it cannot be overlooked that the
sensitivity of the assays may have affected identification
of splice variants (especially at low levels of expression).
Alternatively, these genes may be differentially expressed
in a tissue other than blood. Nevertheless, variation in
splicing regulatory sequences leading to aberrant splicing
is a relatively common occurrence and may explain
some of the signals identified by GWAS [16].
Variant rs2014886, a C > T change in intron 2 of the
TSFM gene, was predicted to create a cryptic donor
splice site within the intron, and transcripts derived
from the use of this cryptic splice site, 38 bp down-
stream of a strong acceptor splice site, are represented
in EST databases [15]. We confirmed that the minor al-
lele of the SNP leads to the production of this alternative
Morrison et al. BMC Genomics 2013, 14:627 Page 7 of 12
http://www.biomedcentral.com/1471-2164/14/627splice product, which includes the 38 bp short exon
within intron 2. Negligible amounts of the insertion
product (referred to as TSFM NV) were expressed from
the transcripts carrying the major (C) allele (Figure 4B).
The difference in age between genotypes in our cohort
for the variant rs2014886 reached statistical significance,
so it is possible that the effects we note for TSFM spli-
cing could be driven by differences in mean age rather
than genotype. The insertion of the novel 38 bp intron
causes a frameshift event leading to the generation of a
premature termination codon at a position 85 bp down-
stream of the insertion. This would in all probability
render the novel transcript susceptible to the nonsense-
mediated decay mRNA surveillance pathway [17]. TSFM
has been identified as a likely candidate gene in multiple
sclerosis susceptibility [18], and its expressio14, para 2n
was recently found to be correlated with a variant that
alters an enhancer region [19]. Therefore, since overall
expression of all TSFM isoforms and of the four refer-
ence sequence isoforms (TSFM WT) was not signifi-
cantly altered by genotype, we conclude that the exon
inclusion caused by the SNP is unlikely to be of func-
tional significance.
The genotype-specific splicing changes of the GSDMB
gene may be of more potential importance. VariantFigure 5 Showing the secondary structure change with the major A a
(http://mfold.rna.albany.edu/?q=mfold). The arrows indicate the positionrs11078928, an A > G change in the acceptor splice site
of intron 5 of the GSDMB gene, is associated with two
separate alternative splicing events. Firstly the major (A)
allele of rs11078928 is associated with exon skipping,
resulting in a splice product missing exons 5–8 (referred
to as GSDMB NV), whereas this does not occur in indi-
viduals carrying the minor (G) allele. The cause of the
deletion is not easy to ascertain, but could be attribut-
able to changes in the RNA secondary structure induced
by this SNP, which could alter binding of the splicing
machinery (Figure 5). It is also possible that another
SNP or SNPs in linkage disequilibrium (LD) with
rs11078928 may be causing this splicing alteration. Al-
though WT GSDMB and total GSDMB expression was
decreased in those carrying the minor allele, these
changes did not reach statistical significance, indicating
that the disease susceptibility may be attributable to a gain
of function effect from the novel transcript, rather than
the amount of the GSDMB transcript pool (Figure 3). It
is difficult however to speculate as to the effect of this
large deletion on GSDMB protein function, since little
is known about the structural function of this protein.
Secondly, we identified that subjects carrying the minor
(G) allele of rs11078928 exhibit skipping of exon 6 of
the gene, with homozygotes for the minor allelellele (right) and the minor allele G (left), as predicted by Mfold
of the variant rs11078928 in the GSDMB transcript sequence.
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containing exon 6).
Taken together, these changes indicate that whilst indi-
viduals homozygous for the major (A) allele do express
the Δ5-8 deleted GSDMB product, they also express the
full length exon 6-containing isoforms. Conversely, indi-
viduals homozygous for the minor (G) allele do not ex-
press either the deleted GSDMB product or the full
length product (isoforms containing exon 6), as reflected
in their lower overall expression. This may suggest some
functional importance of the region of the GSDMB pro-
tein encoded by exon 6, but there is very little information
on the nature of this region in the current literature.
GSDMB encodes for the protein Gasdermin B, which
is a member of the gasdermin-domain containing pro-
tein family. Although the exact function of GSDMB re-
mains unclear, members of the gasdermin-domain
containing family have roles in epithelial cell apoptosis
and in maintaining a differentiated state of epithelial
cells [20]. GSDMB has also been shown to be important
in cancer pathogenesis, with alternative splicing of the
gene being involved in gastrointestinal and hepatic can-
cers [21]. The GSDMB gene contains several conserved
amino acid sequences in the N and C terminal regions
as well as several conserved leucine-rich motifs through-
out the sequence [22]. The deletion product described
here, GSDMB NV, is in frame so would not be subject to
nonsense-mediated decay and could plausibly be trans-
lated into the protein.
Variant rs11078928 is located on chromosome 17q12-
21, in an area which was identified in 2007 to be associ-
ated with asthma susceptibility (rs7216389), as well as
susceptibility to developing several autoimmune dis-
eases, including ulcerative colitis (rs2872507), Crohn’s
disease (rs2872507), type 1 diabetes (rs2290400) and pri-
mary biliary cirrhosis (rs9303277) (see Table 1) [23]. It is
interesting to note that the risk alleles for allergic disease
susceptibility are the alternative to that for autoimmune
disease susceptibility, indicating opposite effects of the
variants on pathogenesis of these diseases [24]. The
minor allele for rs11078928, increases risk for develop-
ing these autoimmune traits (risk allele for type 1 dia-
betes not known) and confers a decreased risk to
developing asthma. This association has been replicated
several times by independent groups and in different
populations, and there has been much debate over po-
tential mechanisms of action and which is the causal
gene(s) in that locus.
GSDMB, ORMDL3 (ORM1-like 3) and ZPBP2 (zona
pellucida binding protein 2) have all been considered
good candidates, as they are all expression quantitative
trait loci, with opposite directions of expression seen
with genotype for ORMDL3/GSDMB and ZPBP2. At
present, the best functional evidence of the mechanismby which the 17q12-21 locus may alter asthma and auto-
immune disease susceptibility comes from two studies
by the same group, who identified a 5.3 kb region over-
lapping the ZPBP2 gene, which is associated with several
gene regulatory marks, including allele-specific chroma-
tin interactions, DNA methylation and promoter activity
[20,25]. It has been hypothesised that this regulatory re-
gion may be involved in long-range chromatin interac-
tions and may influence the expression of any one or all
of the genes GSDMB, ORMDL3 and ZPBP2 [20,25].
ZPBP2 has a well-known role in fertilisation and male
fertility, and it has been proposed that this gene may
play a role in influencing the prevalence of asthma in
the population [25]. ORMDL3 has so far been thought
to be the most promising candidate at this locus, since it
has a role in mediating inflammation, and also has ex-
pression in bronchial epithelial cells, where slightly
higher ORMDL3 expression was found in individuals
with asthma compared to controls [26,27]. GSDMB
shows a diverse expression pattern in tissues, including
expression in the lung, liver, intestine and colon, but
with very low expression in bronchial epithelial cells.
However, it has been suggested that the effect of the
chromosome 17q12-21 locus on multiple diseases may
reflect a more direct role on immune function rather
than any tissue-specific effect [20,28]. The expression of
GSDMB in the thymus and CD8+ and CD4+ T-cells
would increase the plausibility of this inference, espe-
cially given the involvement of type 1 and type 2 im-
mune responses in autoimmune and allergic disease
respectively [20,29].
Although genome-wide analysis of transcript isoform
expression in the CEU HapMap population found no
differences in the expression of GSDMB isoform ratios
associated with the asthma haplotype in LCLs
(lymphoblastoid cell lines) [30], the splicing of GSDMB
has been shown to be associated with genotype of the
related variant rs7216389 in brain and in peripheral
blood mononucleated cells [31]. rs7216389 is in the
same LD block as rs11078928 (r2 0.905, D’1.0), and our
data thus suggest the effect on splicing noted in this,
and in our study may be an effect of the splice site SNP
rs11078928. Interestingly Heinzen et al. found an over-
representation of autoimmune traits associated with spli-
cing quantitative trait loci (sQTLs), which could indicate
the importance of splicing differences in these diseases
[31]. Finally, LCLs may not offer a realistic representa-
tion of regulation of in vivo gene expression [32],
explaining the differences in GSDMB splicing patterns
seen in primary cell types and LCLs.
These data are of course preliminary in nature, and re-
quire further work to assess the potential consequences
of a reduction in GSDMB expression, or an alteration to
the pool of transcripts expressed from the GSDMB gene
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and inflammation. Future studies should focus on the ef-
fect of alterations to the GSDMB isoform pool on factors
such as the inflammatory milieu in other appropriate
cell types to prove causality and further define mechan-
ism. It remains to be seen also if GSDMB splicing
changes are also noted in individuals with asthma and
autoimmune diseases.
Conclusions
To conclude, we have demonstrated that a proportion of
genetic variants identified as susceptibility loci for inflam-
matory or autoimmune disease may act by disrupting the
native splicing patterns of their host genes. Using bioinfor-
matics to identify variants likely to interfere with splicing
patterns, followed by functional evaluation in whole blood,
we have demonstrated alterations in the splicing of the
GSDMB and TSFM genes, which is associated with geno-
type at rs11078928 and rs2014886 respectively. Although
the exon inclusion caused by the variant in TSFM is un-
likely to have any functional significance, our data suggest
that rs11078928 is associated with the production of a
novel GSDMB transcript lacking an internal segment, to-
gether with a change in the ratio of some known isoforms.
This is predicted to result in an almost complete lack of
full length GSDMB mRNA in individuals homozygous for
the minor allele. Although the functional significance of
these changes remains to be determined, our study pro-
vides further evidence that GSDMB is a promising candi-
date gene at the 17q12-21 locus, in altering susceptibility
to various autoimmune diseases, and asthma.
Methods
Identifying candidate genes for splicing analysis
We searched the National Institutes of Health (NIH)
GWAS catalogue (http://www.genome.gov/gwastudies) [5]
to identify SNPs associated with known autoimmune dis-
eases at genome wide significance (P < 5×10-8). We fo-
cussed on inflammatory and autoimmune traits as we had
access to an appropriate tissue, i.e. lymphocyte RNA, to
assess splicing. We defined autoimmune diseases/ inflam-
matory traits as those described in the literature as ‘auto-
immune disease’ or ‘chronic inflammatory disease’.
Next we identified proxy SNPs to these candidates that
had r2 >0.8, and located within 500 kb of the index
variant, using the SNAP Proxy Search tool (http://www.
broadinstitute.org/mpg/snap/ldsearch.php) [33]. The
functional consequence of each SNP on transcription
was then identified using the BioMart function of
Ensembl (http://www.ensembl.org) (Homo sapiens Variation
(dbSNP build 135; ENSEMBL). SNPs labelled as ‘Splice Site’
or ‘Essential Splice Site’ were identified and these SNPs were
analysed in silico using ESE Finder [34,35], Alamut Muta-
tion Interpretation Software (Interactive Biosoftware, Rouen,France), and Flybase from the Berkeley Drosophila Genome
Project (http://www.fruitfly.org/seq_tools/splice.html) [36],
in order to predict how likely a splicing change would
occur as a result of the SNP (Figure 1 and Table 1).
Variants demonstrating good evidence of the capacity
to modify splicing patterns were prioritised for further
transcriptomic analysis in mRNA derived from whole
blood samples from subjects of defined genotype.
Assessment of splice site enrichment for SNPs associated
with inflammatory or autoimmune diseases
To determine the likelihood that SNPs associated with
autoimmune or inflammatory phenotypes were located
in elements responsible for splice site choice by chance
alone, we selected 1000 sets of 338 random SNPs
matched on allele frequency (± 5%) and gene proximity
(± 10 kb). For each set we retrieved all variants in link-
age disequilibrium (r2 >0.8 in 1000 Genomes Phase 1
data in Europeans) and used them to query the BioMart
database using the ‘biomaRt’ package. In each set we cal-
culated the proportion of SNPs identified by BioMart as
‘splice_region_variant’. Finally, we compared the propor-
tion of splice site variants in 338 autoimmune disease
SNPs with proportions identified in 1000 sets of
matched proxies and observed enrichment for splice site
variants by one tailed t-test.
Cohort information and sample collection
The samples used were from the Exeter 10,000 cohort
(http://www.exeter.crf.nihr.ac.uk/). GSDMB and TSFM
total expression, expression of wild-type (WT) and novel
(NV) transcripts, as well as GSDMB isoform specific
expression, were compared between 8–10 individuals
homozygous for the major alleles, 8–10 heterozygous indi-
viduals, and 5–8 individuals homozygous for the minor al-
leles. The individuals included in the cohort were of mixed
gender and were of predominantly White British origin.
20% of the GSDMB WT, NV and isoform-specific expres-
sion cohort had diagnosed autoimmune disease (AA n = 2,
AG n = 2 and GG n = 2), as had 23% of the GSDMB total
expression cohort (AA n = 3, AG n = 2 and GG n = 0) and
21% of the TSHM cohort (CC n = 3, CT n = 1 and TT n =
1). The median ages were as follows: GSDMB WT, NV
and isoform-specific expression: 62 (AA n = 10) 61 (AG n
= 10) 60 (GG n = 5); GSDMB total expression (expression
of WT and alternative transcripts) 60 (AA n = 8) 56 (AG n
= 8) 54 (GG n = 6); TSFM WT, NV and total expression
46 (CC n = 8) 63 (CT n = 8) 37 (TT n = 8). The median
ages between genotypes were compared using the
Kruskal-Wallis H test and did not reach statistical
significance (P < 0.05) in the case of GSDMB. However,
when comparing the median ages for the TSFM cohort,
the differences between the groups of each genotype did
reach statistical significance (P = 0.04). The median BMIs
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pression: 27 (AA) 25 (AG) 26 (GG); GSDMB total expres-
sion 25 (AA) 26 (AG) 25 (GG); TSFM WT, NV and total
expression 25 (CC) 29 (CT) 22 (TT). The median BMIs
were compared using the Kruskal-Wallis H test and did
not reach statistical significant for any of the groups. Me-
dian white blood cell counts were compared using
Kruskal-Wallis H test and did not reach statistical signifi-
cance across any of the groups. Data and statistics for
these parameters are given in Additional file 4. Current
medication and past medical history were known for
the donors. 2.5 ml peripheral blood specimens were
collected using PAXgene technology [37] and extracted
using the PAXgene Blood mRNA kit (Qiagen, Crawley,
UK) according to the manufacturer’s instructions. Re-
search was carried out in accordance with the Helsinki
Declaration, and ethical approval was granted by the
Bristol Regional Ethics Committee (study number 09/
H0106/75). Written informed consent was obtained for
all participants.
SNP genotyping
PCR primers were designed to the area surrounding the SNP.
The primer sequences were as follows: GSDMB forward (5′-
GGTGCGTCTTACCACATCCT-3′), GSDMB reverse (5′-G
GGACTGGAGAAAGGGAACT-3′); TSFM forward (5′-GG
CGAAACCCCATCTCTACT-3′), TSFM reverse (5′- CCCC
CACACTGTCTGACTTT-3′); GCKR forward (5′- CCCTCC
CCTTCTCCTAGACA-3′), GCKR reverse (5′- GCTGATG
ATGGAGGGAAAGA-3′); DLD forward (5′- CCTGAAAT
AGATTTCCCTGACA-3′), DLD reverse (5′- GCCATCAGC
TTTCGTAGCAG-3′); FGFR1OP forward (5′- GAAGGTT
TTTGAGGGGGTAAA-3′), FGFR1OP reverse (5′- TTTCCC
TCTGGTGACTTTGG-3′); STAT2 forward (5′- CACAGA
CTCTGGTGGAGCAA-3′), STAT2 reverse (5′- TGCAGTT
CCTCTGTCACACC-3′); ATXN2L forward (5′- TGGCCAG
AAGAAGGGATAGA-3′), ATXN2L reverse (5′-AGATTCT
GCTGTGGCTGTCC-3′); CLEC2D forward (5′-GGTGCCA
CTTAAAAAGTTATTGG-3′), CLEC2D reverse (5′- AGTG
TGTGGAATGGTTGCTG-3′). 50 ng DNA from the
peripheral blood of healthy controls was amplified by
PCR using MegaMix Royal (Cambio, Cambridge, UK)
under the following conditions: 95°C for 5 min;
followed by 40 cycles of: 95°C for 30s, 60°C for 1 min,
72°C for 1 min; followed by 72°C for 10 min. PCR prod-
ucts were then sequenced to confirm genotype. Se-
quence analysis was carried out using the Mutation
Surveyor software package (SoftGenetics, Pennsylvania,
USA).
RT-PCR and band isolation to identify novel splice
products
PCR primers were designed to at least 2 exons either side of
the SNP of interest. The primer sequences were as follows:GSDMB forward (5′- ACCCTTTTCATTCCGATCAA-3′),
GSDMB reverse (5′- AAGTCCAGAATGGCTTTTGC-3′);
TSFM forward (5′- GGTGTTTATCGCGGCTAGAG -3′),
TSFM reverse (5′- CAGAGGGTTGATCCTTTAGGG -3′);
TSFM NV forward (5′- GACCTCAAACAGACGGAG
TCTTGCT-3′), TSFM NV reverse (5′- TCTTTGGTCTTC
CTCCCTTGGAGC-3′), GCKR forward (5′- GGCTTTCT
CATTGGTGATCACAGTGA-3′), GCKR reverse (5′- AGC
TTGGAGTTGCTAATCCGAAGGT-3′); DLD forward (5′-
CTTGGTGGAACATGCTTGAA-3′), DLD reverse (5′- CC
ATCTGACTTCTTGGTAGCAC-3′), FGFR1OP forward
(5′- TCCTTTAGTTAATGAGAGCCTGAAA-3′), FGFR1OP
reverse (5′ CAGACTTCCTGCTTGCTTCC-3′); STAT
2 forward (5′- TCCTCCTCAATTACAAGGCTTC-3′),
STAT2 reverse (5′- TGCTCAGCTGGTCTGAGTTG-3′);
ATXN2L forward (5′- CCAAGCCCTTTATGCCACT-3′),
ATXN2L reverse (5′- GAAGCTGCTCTGAGGGGACT-3′);
CLEC2D forward (5′- AACCCAGGTTGTCTGCATTC-3′),
CLEC2D reverse (5′- TTCAGTACCATTTATCCATTTCC
A-3′). 100 ng peripheral blood RNA from individuals
of known genotype, was reverse transcribed using
SuperScript®III First-Strand Synthesis System following
the protocol as recommended by the manufacturer
(Invitrogen by Life Technologies, Foster City, USA).
The cDNA was then amplified by PCR using MegaMix
Royal (Cambio, Cambridge, UK) under the following
conditions: 95°C for 5 min; followed by 30 cycles of:
95°C for 30 s, 60°C for 1 min, 72°C for 1 min; followed
by 72°C for 10 min, and the products were separated
on a 2% agarose gel. Novel bands were identified, iso-
lated and amplified using the respective PCR primers
and conditions already described. The amplification
products were then sequenced to confirm identity and
characterise any unusual products.
Real-time PCR to quantify relative expression of isoforms
by genotype
Real-time PCR primers were designed to the reference
sequence (wild-type; WT) and any novel (novel; NV)
transcripts. Where alternatively expressed isoforms were
present in the region of interest, inventoried Taqman
Assays were purchased (Life Technologies, Foster City,
USA), information for which is shown in Additional file
2. Assays for total expression of all wild-type transcripts
as well as the novel transcripts were also purchased. Pri-
mer and probe information for Custom Taqman Assays
are given in Additional file 5, and their relative positions
are indicated in Figures 2 and 3. RNA was reverse tran-
scribed as described previously, and real-time quantita-
tive PCR was performed using the ABI Prism 7900HT
platform. RNA from 5–10 individuals of each genotype
was amplified by this method (10X heterozygotes, 10X
homozygotes for the major allele, 5-10X homozygotes
for the minor allele). Results were analysed using the
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specific alternations in transcript levels.
Assessment of secondary structure change
Pre-spliced hnRNA secondary structure was analysed using
MFOLD software (http://www.bioinfo.rpi.edu/applications/
mfold/), under default settings [39,40].
Statistical analysis
Differences between the expression patterns of normal and
aberrant transcripts according to genotype were assessed
by the Kruskal-Wallis H test. Non-parametric statistics
were necessary due to the relatively small sample numbers
and the expected non-normality of data.
Additional files
Additional file 1: (Additional data file 1.ppt) is a figure showing the
difference in nucleotide sequence between GSDMB WT and GSDMB
NV transcript sequences. The title of the figure is “Electropherogram
showing changes to the GSDMB transcript at the sequence level”.
Additional file 2: (Additional data file 2.csv) is a table showing the
Taqman Assay information, including Assay IDs (Applied Biosystems,
Foster City, USA) along with information about the transcript(s) that the
assay will detect. The title of the table is “Taqman Assay information”.
Additional file 3: (Additional data file 3.ppt) is a figure showing the
difference in nucleotide sequence between TSFM WT and TSFM NV
transcript sequences. The title of the figure is “Electropherogram
showing the changes to the TSFM transcript at the sequence level”.
Additional file 4: (Additional data file 4.docx) is a table giving the
age, BMI, white blood count, Platelet count and haemoglobin
measurements for study participants.
Additional file 5: (Additional data file 5.csv) is a table listing the
Custom Taqman Assay information, including primer and reporter
information, and transcripts detected by the Custom Taqman
Assays, provided by Applied Biosystems (Foster City, USA). The title
of the table is “Custom Taqman Assay information for GSDMB and TSFM”.
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